Receive our newsletter – data, insights and analysis delivered to you
July 8, 2009

AstraZeneca to Press Forward on ADHD and Alzheimer’s Drug Research

AstraZeneca will conduct further development of AZD3480 for attention deficit/hyperactivity disorder (ADHD) and also plans to continue development of AZD1446 (TC-6683) for Alzheimer's disease. The company will press forward on research into the ADHD drug by initiating Phase IIb studies an

By cms admin

AstraZeneca will conduct further development of AZD3480 for attention deficit/hyperactivity disorder (ADHD) and also plans to continue development of AZD1446 (TC-6683) for Alzheimer’s disease.

The company will press forward on research into the ADHD drug by initiating Phase IIb studies and has agreed to make a $10m milestone payment to Targacept to continue researching the drug.

Targacept is a biopharmaceutical company that designs, discovers and develops drugs for nervous system diseases and disorders.

AZD1446 for Alzheimer’s disease is currently in Phase I, and was discovered in the ongoing AstraZeneca-Targacept research collaboration.

The company has prioritised the development of AZD1446 over further development of AZD3480. AZD3480 and AZD1446 are selective alpha4beta2 NNR agonists.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU